Search all trials

Find therapies in clinical trials near you – page 12

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Bladder cancer+2

Not recruiting

Registered drug

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo

Spain

Participants:65+ years
Substances:Anakinra

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

InvestigationalNo placebo

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Registered drug

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Enzalutamide

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Registered drugNo placebo

Study of Loncastuximab Tesirine and Rituximab for Untreated Unfit or Frail Patients with Diffuse Large B-cell Lymphoma

Registered drugNo placebo

Spain

Participants:65+ years
Substances:Adct-402

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Registered drug

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Darolutamide

Contact Research Centre

Neoplasm malignant

Not recruiting

InvestigationalNo placebo

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Darolutamide

Contact Research Centre

Breast cancer+2

Not recruiting

Registered drugNo placebo

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Ovarian epithelial cancer

Not recruiting

Registered drug

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Anhydrous Docetaxel

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Find therapies in clinical trials near you – page 12

150 trials match your criteria

Bladder cancer+2

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Hormone receptor positive breast cancer+1

Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

Malignant melanoma

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Hormone receptor positive HER2 negative breast cancer

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

Hormone-refractory prostate cancer+1

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Diffuse large B-cell lymphoma

Study of Loncastuximab Tesirine and Rituximab for Untreated Unfit or Frail Patients with Diffuse Large B-cell Lymphoma

Prostate cancer metastatic

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Neoplasm malignant

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

Breast cancer+2

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Ovarian epithelial cancer

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Breast cancer metastatic+1

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.